In any case, it should be noted that the magnitude and direction of this balance cannot be generalizable to all LDL‐lowering interventions or to high‐risk patients' populations (i.e., those with homozygous FH), in whom the benefits of ApoB‐pathway inactivation may outweigh potential hepatic liabilities. Here, APOB is linked to familial hyperaldosteronism.